TargetMol
Siramesine (Lu 28-179) hydrochloride is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of Y cells and to exhibit a potent anticancer activity in vivo.
More Information
Supplier Page
CGK733
50 mg
| Purity Not Available
TargetMol
CGK733
10 mg
| Purity Not Available
TargetMol
ML347
10 mg
| 99.71%
TargetMol
ML347(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.
More Information
Supplier Page
ML347
50 mg
| 99.71%
TargetMol
ML347(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.
More Information
Supplier Page
ML347
5 mg
| 99.71%
TargetMol
ML347(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.
More Information
Supplier Page
PF-4708671
10 mg
| Purity Not Available
TargetMol
PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) .In cell-free assays, PF-4708671(PF4708671) is potent for S6K1(Ki50=20 nM, IC50=160 nM).
More Information
Supplier Page
PF-4708671
100 mg
| Purity Not Available
TargetMol
PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) .In cell-free assays, PF-4708671(PF4708671) is potent for S6K1(Ki50=20 nM, IC50=160 nM).
More Information
Supplier Page
TargetMol
Asenapine Maleate (Org 5222 maleate) is a second generation (atypical) antipsychotic agent that is taken sublingually and used in the treatment of schizophrenia and manic or mixed episodes associated with bipolar 1 disorder. Asenapine is associated with a low rate of transient and mild serum aminotransferase elevations during therapy but has not been linked to […]
More Information
Supplier Page
TargetMol
Asenapine Maleate (Org 5222 maleate) is a second generation (atypical) antipsychotic agent that is taken sublingually and used in the treatment of schizophrenia and manic or mixed episodes associated with bipolar 1 disorder. Asenapine is associated with a low rate of transient and mild serum aminotransferase elevations during therapy but has not been linked to […]
More Information
Supplier Page